Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 42 entries
Sorted by: Best Match Show Resources per page
Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

United European gastroenterology journal

Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T.
PMID: 27403304
United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13.

BACKGROUND AND AIM: This prospective randomized study was designed to assess the efficacy of 10-day and 14-day rifabutin-based triple therapy as a third- or fourth-line rescue therapy.METHODS: Patients who failed first- and second-line eradication therapy were enrolled. H. pylori...

Cite
Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J. 2015;4(3):380-7doi: 10.1177/2050640615618043.
Mori, H., Suzuki, H., Matsuzaki, J., Tsugawa, H., Fukuhara, S., Miyoshi, S., Hirata, K., Seino, T., Matsushita, M., Nishizawa, T., Masaoka, T., & Kanai, T. (2016). Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European gastroenterology journal, 4(3), 380-7. https://doi.org/10.1177/2050640615618043
Mori, Hideki, et al. "Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study." United European gastroenterology journal vol. 4,3 (2016): 380-7. doi: https://doi.org/10.1177/2050640615618043
Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13. PMID: 27403304; PMCID: PMC4924440.
Copy Download .nbib Format: NLM
Biotransformations of rifamycins: process possibilities.

Biotechnology advances

Banerjee UC, Saxena B, Chisti Y.
PMID: 14543707
Biotechnol Adv. 1992;10(4):577-95. doi: 10.1016/0734-9750(92)91454-m.

Rifampicin, an important antibiotic, is manufactured by chemical conversion of rifamycin S which is obtained by the chemical modification of rifamycin B. Rifamycin B is a product of Nocardia mediterranei fermentations. The chemical conversion of rifamycin B to rifamycin...

Cite
Banerjee UC, Saxena B, Chisti Y. Biotransformations of rifamycins: process possibilities. Biotechnol Adv. 1992;10(4):577-95doi: 10.1016/0734-9750(92)91454-m.
Banerjee, U. C., Saxena, B., & Chisti, Y. (1992). Biotransformations of rifamycins: process possibilities. Biotechnology advances, 10(4), 577-95. https://doi.org/10.1016/0734-9750(92)91454-m
Banerjee, U C, et al. "Biotransformations of rifamycins: process possibilities." Biotechnology advances vol. 10,4 (1992): 577-95. doi: https://doi.org/10.1016/0734-9750(92)91454-m
Banerjee UC, Saxena B, Chisti Y. Biotransformations of rifamycins: process possibilities. Biotechnol Adv. 1992;10(4):577-95. doi: 10.1016/0734-9750(92)91454-m. PMID: 14543707.
Copy Download .nbib Format: NLM
Tuberculosis Infection in Children and Adolescents: Testing and Treatment.

Pediatrics

Nolt D, Starke JR.
PMID: 34851422
Pediatrics. 2021 Dec 01;148(6). doi: 10.1542/peds.2021-054663.

Tuberculosis (TB) remains an important problem among children in the United States and throughout the world. There is no diagnostic reference standard for latent tuberculosis infection (also referred to as tuberculosis infection [TBI]). The tuberculin skin test (TST) has...

Cite
Nolt D, Starke JR. Tuberculosis Infection in Children and Adolescents: Testing and Treatment. Pediatrics. 2021;148(6)doi: 10.1542/peds.2021-054663.
Nolt, D., & Starke, J. R. (2021). Tuberculosis Infection in Children and Adolescents: Testing and Treatment. Pediatrics, 148(6), . https://doi.org/10.1542/peds.2021-054663
Nolt, Dawn, and Starke, Jeffrey R. "Tuberculosis Infection in Children and Adolescents: Testing and Treatment." Pediatrics vol. 148,6 (2021). doi: https://doi.org/10.1542/peds.2021-054663
Nolt D, Starke JR. Tuberculosis Infection in Children and Adolescents: Testing and Treatment. Pediatrics. 2021 Dec 01;148(6). doi: 10.1542/peds.2021-054663. PMID: 34851422.
Copy Download .nbib Format: NLM
Targeting Non-Replicating .

International journal of molecular sciences

Egorova A, Salina EG, Makarov V.
PMID: 34948114
Int J Mol Sci. 2021 Dec 10;22(24). doi: 10.3390/ijms222413317.

Latent tuberculosis infection (LTBI) represents a major challenge to curing TB disease. Current guidelines for LTBI management include only three older drugs and their combinations-isoniazid and rifamycins (rifampicin and rifapentine). These available control strategies have little impact on latent...

Cite
Egorova A, Salina EG, Makarov V. Targeting Non-Replicating . Int J Mol Sci. 2021;22(24)doi: 10.3390/ijms222413317.
Egorova, A., Salina, E. G., & Makarov, V. (2021). Targeting Non-Replicating . International journal of molecular sciences, 22(24), . https://doi.org/10.3390/ijms222413317
Egorova, Anna, et al. "Targeting Non-Replicating ." International journal of molecular sciences vol. 22,24 (2021). doi: https://doi.org/10.3390/ijms222413317
Egorova A, Salina EG, Makarov V. Targeting Non-Replicating . Int J Mol Sci. 2021 Dec 10;22(24). doi: 10.3390/ijms222413317. PMID: 34948114.
Copy Download .nbib Format: NLM
Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates.

Frontiers in chemistry

Surur AS, Sun D.
PMID: 33996753
Front Chem. 2021 Apr 30;9:659845. doi: 10.3389/fchem.2021.659845. eCollection 2021.

The tale of abate in antibiotics continued defense mechanisms that chaperone the rise of drug-defying superbugs-on the other hand, the astray in antibacterial drug discovery and development. Our salvation lies in circumventing the genesis of resistance. Considering the competitive...

Cite
Surur AS, Sun D. Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates. Front Chem. 2021;9:659845doi: 10.3389/fchem.2021.659845.
Surur, A. S., & Sun, D. (2021). Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates. Frontiers in chemistry, 9659845. https://doi.org/10.3389/fchem.2021.659845
Surur, Abdrrahman Shemsu, and Sun, Dianqing. "Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates." Frontiers in chemistry vol. 9 (2021): 659845. doi: https://doi.org/10.3389/fchem.2021.659845
Surur AS, Sun D. Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates. Front Chem. 2021 Apr 30;9:659845. doi: 10.3389/fchem.2021.659845. eCollection 2021. PMID: 33996753; PMCID: PMC8120311.
Copy Download .nbib Format: NLM
High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis.

The Journal of infection

Wetzstein N, Kessel J, Bingold TM, Carney J, Graf C, Koch BF, Meier F, Baumgarten J, Küpper-Tetzel CP, Khodamoradi Y, Wolf T, Schüttfort G, Vehreschild MJGT, Wichelhaus TA, Stephan C.
PMID: 34788633
J Infect. 2021 Nov 14; doi: 10.1016/j.jinf.2021.10.027. Epub 2021 Nov 14.

INTRODUCTION: Mycobacterium genavense is a fastidious slow growing mycobacterium (SGM) that causes disseminated infections in immunocompromised hosts. It has been described in HIV-positive individuals and increasingly in patients without HIV. The infections are difficult to treat and the optimal...

Cite
Wetzstein N, Kessel J, Bingold TM, et al. High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis. J Infect. 2021;doi: 10.1016/j.jinf.2021.10.027.
Wetzstein, N., Kessel, J., Bingold, T. M., Carney, J., Graf, C., Koch, B. F., Meier, F., Baumgarten, J., Küpper-Tetzel, C. P., Khodamoradi, Y., Wolf, T., Schüttfort, G., Vehreschild, M. J. G. T., Wichelhaus, T. A., & Stephan, C. (2021). High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis. The Journal of infection, . https://doi.org/10.1016/j.jinf.2021.10.027
Wetzstein, Nils, et al. "High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis." The Journal of infection vol. (2021). doi: https://doi.org/10.1016/j.jinf.2021.10.027
Wetzstein N, Kessel J, Bingold TM, Carney J, Graf C, Koch BF, Meier F, Baumgarten J, Küpper-Tetzel CP, Khodamoradi Y, Wolf T, Schüttfort G, Vehreschild MJGT, Wichelhaus TA, Stephan C. High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis. J Infect. 2021 Nov 14; doi: 10.1016/j.jinf.2021.10.027. Epub 2021 Nov 14. PMID: 34788633.
Copy Download .nbib Format: NLM
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

Evidence-based child health : a Cochrane review journal

Sharma SK, Sharma A, Kadhiravan T, Tharyan P.
PMID: 25404581
Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962.

BACKGROUND: Preventing active tuberculosis (TB) from developing in people with latent tuberculosis infection (LTBI) is important for global TB control. Isoniazid (INH) for six to nine months has 60% to 90% protective efficacy, but the treatment period is long,...

Cite
Sharma SK, Sharma A, Kadhiravan T, et al. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evid Based Child Health. 2014;9(1):169-294doi: 10.1002/ebch.1962.
Sharma, S. K., Sharma, A., Kadhiravan, T., & Tharyan, P. (2014). Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evidence-based child health : a Cochrane review journal, 9(1), 169-294. https://doi.org/10.1002/ebch.1962
Sharma, Surendra K, et al. "Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB." Evidence-based child health : a Cochrane review journal vol. 9,1 (2014): 169-294. doi: https://doi.org/10.1002/ebch.1962
Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962. PMID: 25404581.
Copy Download .nbib Format: NLM
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients.

HIV/AIDS (Auckland, N.Z.)

Putcharoen O, Kerr SJ, Ruxrungtham K.
PMID: 24068877
HIV AIDS (Auckl). 2013 Sep 16;5:231-41. doi: 10.2147/HIV.S25712.

Non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) are an important component of combination antiretroviral regimens. Amongst the NNRTIs, efavirenz is commonly recommended for initial regimens in treatment-naïve HIV patients, but its use in some settings is limited by adverse effects,...

Cite
Putcharoen O, Kerr SJ, Ruxrungtham K. An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients. HIV AIDS (Auckl). 2013;5:231-41doi: 10.2147/HIV.S25712.
Putcharoen, O., Kerr, S. J., & Ruxrungtham, K. (2013). An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients. HIV/AIDS (Auckland, N.Z.), 5231-41. https://doi.org/10.2147/HIV.S25712
Putcharoen, Opass, et al. "An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients." HIV/AIDS (Auckland, N.Z.) vol. 5 (2013): 231-41. doi: https://doi.org/10.2147/HIV.S25712
Putcharoen O, Kerr SJ, Ruxrungtham K. An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients. HIV AIDS (Auckl). 2013 Sep 16;5:231-41. doi: 10.2147/HIV.S25712. PMID: 24068877; PMCID: PMC3782505.
Copy Download .nbib Format: NLM
Current management options for latent tuberculosis: a review.

Infection and drug resistance

Norton BL, Holland DP.
PMID: 23226700
Infect Drug Resist. 2012;5:163-73. doi: 10.2147/IDR.S29180. Epub 2012 Nov 29.

Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the...

Cite
Norton BL, Holland DP. Current management options for latent tuberculosis: a review. Infect Drug Resist. 2012;5:163-73doi: 10.2147/IDR.S29180.
Norton, B. L., & Holland, D. P. (2012). Current management options for latent tuberculosis: a review. Infection and drug resistance, 5163-73. https://doi.org/10.2147/IDR.S29180
Norton, Brianna L, and Holland, David P. "Current management options for latent tuberculosis: a review." Infection and drug resistance vol. 5 (2012): 163-73. doi: https://doi.org/10.2147/IDR.S29180
Norton BL, Holland DP. Current management options for latent tuberculosis: a review. Infect Drug Resist. 2012;5:163-73. doi: 10.2147/IDR.S29180. Epub 2012 Nov 29. PMID: 23226700; PMCID: PMC3514970.
Copy Download .nbib Format: NLM
Recent advances in tuberculosis: New drugs and treatment regimens.

Current respiratory medicine reviews

Sloan DJ, Davies GR, Khoo SH.
PMID: 24683386
Curr Respir Med Rev. 2013 Jun 01;9(3):200-210. doi: 10.2174/1573398x113099990017.

The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic...

Cite
Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev. 2013;9(3):200-210doi: 10.2174/1573398x113099990017.
Sloan, D. J., Davies, G. R., & Khoo, S. H. (2013). Recent advances in tuberculosis: New drugs and treatment regimens. Current respiratory medicine reviews, 9(3), 200-210. https://doi.org/10.2174/1573398x113099990017
Sloan, Derek J, et al. "Recent advances in tuberculosis: New drugs and treatment regimens." Current respiratory medicine reviews vol. 9,3 (2013): 200-210. doi: https://doi.org/10.2174/1573398x113099990017
Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev. 2013 Jun 01;9(3):200-210. doi: 10.2174/1573398x113099990017. PMID: 24683386; PMCID: PMC3968807.
Copy Download .nbib Format: NLM
Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis.

Gut pathogens

Brauer M, Herrmann J, Zühlke D, Müller R, Riedel K, Sievers S.
PMID: 34991700
Gut Pathog. 2022 Jan 06;14(1):4. doi: 10.1186/s13099-021-00475-9.

The anaerobic, gastrointestinal pathogen Clostridioides difficile can cause severe forms of enterocolitis which is mainly mediated by the toxins it produces. The RNA polymerase inhibitor Fidaxomicin is the current gold standard for the therapy of C. difficile infections due...

Cite
Brauer M, Herrmann J, Zühlke D, et al. Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis. Gut Pathog. 2022;14(1):4doi: 10.1186/s13099-021-00475-9.
Brauer, M., Herrmann, J., Zühlke, D., Müller, R., Riedel, K., & Sievers, S. (2022). Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis. Gut pathogens, 14(1), 4. https://doi.org/10.1186/s13099-021-00475-9
Brauer, Madita, et al. "Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis." Gut pathogens vol. 14,1 (2022): 4. doi: https://doi.org/10.1186/s13099-021-00475-9
Brauer M, Herrmann J, Zühlke D, Müller R, Riedel K, Sievers S. Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis. Gut Pathog. 2022 Jan 06;14(1):4. doi: 10.1186/s13099-021-00475-9. PMID: 34991700; PMCID: PMC8739712.
Copy Download .nbib Format: NLM
Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Le X, Guo X, Sun J, Liu L, Shen Y, Wang J, Qi T, Wang Z, Tang Y, Song W, Yin L, Zhang L, Zhang R, Chen J.
PMID: 34999246
Int J Infect Dis. 2022 Jan 06; doi: 10.1016/j.ijid.2022.01.001. Epub 2022 Jan 06.

BACKGROUND: Rifamycins are the cornerstone of anti-tuberculosis therapy while they are potent inducer of drug metabolizing enzymes. For the first time, we evaluated the effect of rifampicin (RIF) and rifabutin (RBT) on the pharmacokinetics (PK) of dolutegravir (DTG) in...

Cite
Le X, Guo X, Sun J, et al. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex. Int J Infect Dis. 2022;doi: 10.1016/j.ijid.2022.01.001.
Le, X., Guo, X., Sun, J., Liu, L., Shen, Y., Wang, J., Qi, T., Wang, Z., Tang, Y., Song, W., Yin, L., Zhang, L., Zhang, R., & Chen, J. (2022). Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, . https://doi.org/10.1016/j.ijid.2022.01.001
Le, Xiaoqin, et al. "Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex." International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases vol. (2022). doi: https://doi.org/10.1016/j.ijid.2022.01.001
Le X, Guo X, Sun J, Liu L, Shen Y, Wang J, Qi T, Wang Z, Tang Y, Song W, Yin L, Zhang L, Zhang R, Chen J. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex. Int J Infect Dis. 2022 Jan 06; doi: 10.1016/j.ijid.2022.01.001. Epub 2022 Jan 06. PMID: 34999246.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 42 entries